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jABSTRACT
Background: The labeling for colchicine (indicated
for acute gout flares or prophylaxis) includes strict
advisories regarding drug–drug and drug–food in-
teractions, including warnings against consuming
grapefruit or grapefruit juice during treatment. Two
of the furocoumarins in grapefruit juice and Seville
orange juice can inhibit intestinal cytochrome P450
(CYP) isozyme 3A4 and P-glycoprotein (involved in
colchicine metabolism and transport). Severe toxic-
ities in patients consuming these juices while taking
other drugs metabolized through these pathways
have been reported.
Objective: Two Phase I studies assessed the effects of
multiple daily consumptions of Seville orange juice or
grapefruit juice on the pharmacokinetic properties of col-
chicine in healthy volunteers.
Methods: Healthy volunteers were enrolled in 2
open-label, Phase I studies. Undiluted juice (240 mL)
was administered twice daily for 4 days. Pharmacoki-
netic data were obtained following a single 0.6-mg
dose of colchicine before the administration of juice
and again following a single 0.6-mg dose of colchicine
on the final day of juice administration. In each study,
blood samples for pharmacokinetics were collected be-
fore dosingwith colchicine and at 0.5, 1, 1.5, 2, 3, 4, 5, 6,
8, 12, and 24 hours postdose. All subjects were moni-
tored for adverse events (AEs) throughout the confine-
ment portion of the study and were queried at the outpa-
tient visits. AEs were coded according to corresponding
MedDRA-coded system organ classes.
Results: Forty-four subjects received either grape-
fruit juice (72.7% male; 90.9% white) or Seville or-
ange juice (62.5% female; 100%white). Although it is
considered to be a moderate concentration-depen-
dent CYP3A4 inhibitor, grapefruit juice did not sig-
nificantly affect the pharmacokinetic parameters of
colchicine. When colchicine was administered with
October 2012Seville orange juice, a moderate inhibitor, Cmax and
UC were decreased by 24% and 20%, respec-
ively. Seville orange juice also caused, on average, a
-hour delay in Tmax. Colchicine in combination with
grapefruit or Seville orange juice was well tolerated.
There were no significant treatment-related AEs re-
ported, and the most likely AEs were general gastroin-
testinal events.
Conclusions: In contrast to label warnings based on
the literature, grapefruit juice did not affect the pharma-
cokinetics of colchicine. Seville orange juice paradoxi-
cally reduced absorption of colchicine and increased
Tmax, but the clinical significance of this is unknown.
Contrary to the expected effects of inhibiting the enzymes
that metabolize colchicine, neither juice increased expo-
sure to colchicine. However, the absence of a positive
control in these studies dictates that caution should be
usedwhen applying these results clinically. ClinicalTrials.
gov identifiers: NCT00960193 and NCT00984009.
(Clin Ther. 2012;34:2161–2173) © 2012 Elsevier HS
ournals, Inc.
Key words: colchicine, drug interaction, grapefruit
uice, pharmacokinetics, Seville orange juice.
INTRODUCTION
Consumption of citrus products in the United States is
common, and grapefruit is consumed for its health
benefits as a citrus fruit that is low in calories and rich
in vitamin C, potassium, and dietary fiber. The poten-
tial for grapefruit juice to interact with medications
Data from this study were presented in part in abstract and poster
format at the Annual Meeting of the American Society for Clinical Phar-
macology and Therapeutics; March 2–5, 2011; Dallas, Texas.
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Clinical Therapeuticswas first discovered in 1989.1 It was subsequently re-
orted that healthy subjects who took the calcium
hannel antagonist felodipine with grapefruit juice had
igher felodipine plasma concentrations than did those
ho took the drug with water; the higher plasma felo-
ipine concentrations resulted in a more pronounced
ffect of felodipine in terms of decreased blood pres-
ure and other untoward effects after ingesting as little
s a single 240-mL glass of grapefruit juice.2 It has
since been established andwell documented in the pub-
lished literature that grapefruit juice is a mechanism-
based inhibitor of intestinal, and not hepatic, cyto-
chrome P450 (CYP) 3A4 isozyme (intestinal first-pass
metabolism).3 Grapefruit juice can cause increases in
oral bioavailability and prolongation in the elimina-
tion half-life of a wide range of other drugs that are
CYP3A4 substrates, which can result in increased sys-
temic drug exposure (for recent reviews, see Seden et
al,4 Won et al,5 and Hanley et al6). It has also been
eported that Seville orange juice has the same poten-
ial as does grapefruit juice for causing food–drug in-
eractions due to the inhibition of intestinal CYP3A4.7
Both grapefruit juice and Seville orange juice contain
furocoumarins, of which bergamottin and 6=,7=-dihy-
droxybergamottin are the main constituents and are
presumed to be the primary compounds effecting
CYP3A4 inhibition.7 Both grapefruit and Seville or-
nges are believed to be hybrids of pomelo (pum-
ello),8 the juice of which also contains furocoumarins
at concentrations similar to those in grapefruit juice.9
Medications metabolized by intestinal CYP3A4 en-
zyme have either a low oral bioavailability or are
known to be narrow therapeutic index drugs and are
more likely to have clinically significant interactions
when coadministered with grapefruit juice and/or Sev-
ille orange juice.
Gout, once viewed as a condition of wealthy, over-
indulging, overweight men, now affects 8.3 million
Americans (3.9% of the adult population).10 Gout is a
ainful and progressive disease that, if inadequately
reated, may lead to joint destruction and deformity,
ith severely compromised quality of life. In most pa-
ients experiencing a flare, recurrent flares are likely
nd, if untreated, are associated with an increased fre-
uency and severity of flares.11 The increase in the
revalence of gout has been linked to increased longev-
ty (urate levels rise with age) and unhealthy dietary
nd lifestyle trends.12 The prevalences of associated
comorbidities, including obesity, hypertension, meta-
2162bolic syndrome, and type 2 diabetes mellitus, have also
increased. Therefore, patients with gout often have a
number of other concomitant conditions that also re-
quire medications.
Colchicine is a substrate of P-glycoprotein (P-gp),13
a key protein involved in the multidrug resistance
(MDR-1) transport system located in the cell mem-
branes of numerous tissues, and is excreted by both
renal and hepatic mechanisms involving P-gp efflux
of colchicine across membranes.14,15 P-gp also plays
a role in the known incomplete absorption of colchi-
cine (mean absolute bioavailability,45%).16 P-gp–
mediated secretion into the intestine and reabsorp-
tion/biliary recirculation occur, as evidenced by
secondary peak plasma concentrations and the ex-
cretion of parent colchicine in feces.16–18 Absorbed
olchicine is metabolized to a lesser extent (5%)
nto inactive oxidative metabolites by intestinal and
epatic CYP3A4.17,18
Colchicine, used for 200 years to treat acute gout
flares, plays a pivotal role in both the treatment of gout
flares as well as long-term prophylaxis. The approved
dosing regimen for acute gout attacks requires a single
dose of 1.2 mg to be taken immediately on the first
signs of an acute flare, followed by a 0.6-mg dose 1
hour later, and the regimen for prophylaxis is 0.6 mg
once or twice daily.
Colchicine is generally well tolerated when used at
low doses, although its therapeutic index is relatively
narrow. Any interaction that results in increased
plasma colchicine concentrations can potentially lead
to toxicity that may be severe and dangerous. One
established cause of severe colchicine-induced toxicity
is the coadministration of colchicine with other drugs
that inhibit the metabolism of colchicine. Patients with
gout are often obese and/or have various comorbidities
(eg, renal impairment, metabolic syndrome, diabetes
mellitus, dyslipidemia, cardiovascular disease) that re-
quire medical treatment with other modalities,19–21
which can increase the risk for drug–drug interactions.
The US Food and Drug Administration (FDA) Adverse
Event Reporting System database has reported that
when colchicine is coadministered with certain P-gp or
CYP3A4 inhibitors, the risk for serious adverse events
(AEs), including fatalities and life-threatening condi-
tions, is increased.22
As a part of the colchicine drug-development pro-
gram to identify other coadministered drugs and foods
that may alter colchicine concentrations, and to further
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tion in the product labeling, a series of drug–drug and
food–drug interaction studies have been conducted by
the only manufacturer of FDA-approved colchicine.
The intent was to provide clear colchicine dose-adjust-
ment guidelines to be used in patients in whom colchi-
cine is combined with various CYP3A4 enzyme and/or
P-gp transport inhibitors.23 Two food–drug interac-
ion studies were included in this program; each eval-
ated the effects of multiple daily consumptions of
rapefruit juice or Seville orange juice on the pharma-
okinetic properties of a single 0.6-mg oral dose of
olchicine in healthy adult volunteers. The results of
hese 2 studies are reported here.
METHODS
The 2 separate studies—study 1 (grapefruit juice) and
study 2 (Seville orange juice)—followed similar proto-
cols. The primary objective of each study was to deter-
mine the effects of multiple daily consumptions of
grapefruit juice or Seville orange juice (240 mL twice
daily for 4 consecutive days) on the pharmacokinetic
properties of a single 0.6-mg oral dose of colchicine
administered to healthy adult subjects under fasting
conditions. The secondary objective of each study was
to assess the tolerability of a single 0.6-mg oral dose of
colchicine administered with and without multiple
daily consumptions of grapefruit juice or Seville orange
juice.
An extraction procedure using solid-phase extrac-
tion and analysis of the extract by liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS) was de-
veloped and validated for the determination of
colchicine in human plasma containing K2-EDTA as
the anticoagulant. The standard curve ranged from
0.2000 to 40.00 ng/mL. Standards and quality control
(QC) samples were thawed, mixed on a vortex mixer,
spiked with internal standard (colchicine-d3), and ex-
tracted. The extracts were dried under nitrogen, recon-
stituted, and analyzed using an API 5000 LC-MS/MS
equipped with a turbo ion spray source. The multiple
reaction monitoring mode was used to monitor the
precursor and product ions for the analytes, colchicine,
and the internal standard. The analyte and internal
standard peak areas were exported to Watson LIMS
(Thermo Fisher Scientific Inc., Rochester, New York)
to create a calibration curve using weighted (1/x) least
squares regression fit to a linear model. The concentra- m
October 2012tions of the standards, QCs, and samples were calcu-
lated using Watson LIMS.
The validity of each batch run during subject anal-
ysis was determined by evaluating the accuracy of stan-
dards and QCs. A batch run was accepted if the stan-
dards and QCs passed acceptability criteria. The
accuracy and precision of the validation of the bioana-
lytical method for colchicine was accomplished by an-
alyzing 3 standard curves prepared in human plasma
and consisting of 9 concentrations prepared in dupli-
cate in 3 separate batches. QCs were also prepared to
assess accuracy, precision, and stability. The standard
curve concentrations ranged from 0.2000 to 40.00
ng/mL. The concentrations of the QCs were 0.2000,
0.6000, 3.200, 16.00, and 32.00 ng/mL.
Accuracy was defined as the difference between
the mean of a set of results and the “true” value
(reported as a percentage; %bias). Precision was de-
fined as the %CV of individual replicates from the
calculated values. The between-batch accuracy for
standards was between 98.57% and 101.92%, while
precision was5.60%. The between-batch accuracy
of QCs was between 101.17% and 106.22%, while
precision was6.38%. The between-batch accuracy
for standards was between 98.57% and 101.92%,
while precision was5.60%. The between-batch ac-
curacy of QCs was between 101.17% and 106.22%,
while precision was 6.38%. Within-batch accu-
racy and precision were assessed by analyzing 6 rep-
licates of QCs at 5 different concentrations (0.2000,
0.6000, 3.200, 16.00, and 32.00 ng/mL). The with-
in-batch accuracy ranged from 96.75% to 109.17%,
and precision was 5.93%. This method was dem-
onstrated to accurately and precisely quantify all
standards and QC samples.
Subjects
Subjects in each study were recruited using identical
recruitment criteria. Nonobese (body mass index,
18–32 kg/m2) adults aged 18 to 45 years of either sex
onsidered healthy on the basis of medical history,
hysical examination, routine laboratory tests (espe-
ially for renal and hepatic function), vital signs, and
CG were eligible for entry into the studies. All sub-
ects had to be nonsmokers (including use of nicotine-
ontaining products) for6months.Women had to be
urgically sterile (hysterectomy or bilateral oophorec-
omy) or had undergone bilateral tubal ligation 6
onths before study entry, be sexually inactive for
2163
Clinical Therapeutics14 days before the first dose and throughout the
study, have sexual activity restricted to a partner who
had undergone surgical sterilization 6 months prior,
or undertake a reliable method of contraception (oral,
injectable, topical, or intravaginal hormone contracep-
tion for 3 months; nonhormonal intrauterine device
for 3 months and throughout the study; or a barrier
method with spermicide for 14 days before the first
dose and throughout the study). Exclusion criteria in-
cluded known allergy to colchicine; inability to con-
sume, or food allergy to, grapefruit juice or Seville or-
ange juice (depending on the study); history or
presence of significant cardiovascular, pulmonary, he-
patic, gallbladder or biliary tract, renal, hematologic,
gastrointestinal (GI), endocrine, immunologic, derma-
tologic, neurologic, or psychiatric disease; use of any
drugs or substances known to inhibit CYP enzymes
and/or P-gp in the 4 weeks before the first dose and
throughout the study; positive test result for HIV or
hepatitis B or C at screening; history or evidence of
alcoholism or drug abuse in the previous 2 years; active
sexually transmitted disease; use of a special diet in the
4 weeks before the first dose; reported difficulty in fast-
ing or consuming standardized meals; hemoglobin
11.5 g/dL; inadequate venous access for repeated ve-
nipuncture; blood donation of 50 to 499 mL within 4
weeks and 499 mL within 8 weeks before the first
Colchicine 0.6 mg
on day 1 (AM)
4-Wk
screening
period
Day 1
2-Wk
washout period
Colchicine serial blood samples
for 24 hours during clinic confinement
on days 1–2
Ci
B
Figure 1. Study design.dose; blood donation of 500 mL in 2 weeks, 1500
2164mL in 6 months, or2500 mL in 1 year at completion
of the study; donation of plasma in the 4 weeks before
the first dose; participation in any other clinical trial
within 4 weeks before the first dose; and pregnancy or
breastfeeding in women.
Study Design
The subjects were recruited and studied at a single
US clinical study center (Cetero Research, Fargo,
North Dakota), and the study protocols received ap-
proval from the institutional review board at PRACS
Institute, Ltd (Fargo, North Dakota). All subjects pro-
vided written informed consent before participation in
the studies, which were conducted in accordance with
the US Code of Federal Regulations and International
Conference on Harmonisation Guidelines for Good
Clinical Practice and adhered to the ethical principles
of the Declaration of Helsinki.
The design of each studywas identical except for the
type of citrus juice administered (grapefruit juice vs
Seville orange juice) (Figure 1). These Phase I, open-
label, nonrandomized, 1-sequence, 2-period pharma-
cokinetic food–drug interaction studies evaluated the
effects of the consumption of 240 mL of citrus juice
(grapefruit juice or Seville orange juice in the respective
studies) twice daily for 4 consecutive days on the sin-
gle-dose pharmacokinetic properties of colchicine
Days 15–18
Colchicine 0.6 mg
+ citrus juice 240 mL
on day 18 (AM)
Colchicine serial blood samples
for 24 hours during clinic confinement
on days 18–19
ce 240 mL
 and PM)
 daystrus jui
ID (AM
for 4(0.6-mg tablet) in a fasting state. Following a 4-week
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S. Wason et al.screening period (days 28 to 2), subjects were
treated with colchicine 0.6 mg given with 240 mL of
water on the morning of day 1 at 7:15 AM. After a
washout period14 days, subjects received citrus juice
(grapefruit juice or Seville orange juice) 240 mL twice
daily on days 15 to 18 at 7:15 AM and 7:15 PM; when
not confined, the subjects visited the clinic on a non-
confined basis to receive administration of citrus juices.
Study subjects then received a single dose of colchicine
0.6 mg in combination with 240 mL of citrus juice on
the morning of day 18. Subjects were admitted to the
clinical facility for 36 hours (12 hours before dos-
ing and through 24 hours after dosing) for each pe-
riod of colchicine dosing alone and in combination
with citrus juices (days 1 to 2 and days 17 to 19,
respectively). Subjects were dosed in pairs at 1-minute
intervals as a single cohort and in the same sequence
during each test period. Colchicine doses were admin-
istered after completing an overnight fast (10 hours).
Compliance was confirmed by oral cavity and hand
inspection. No foodwas permitted until4 hours after
dosing. During clinic confinement on days 1 and 18,
standardized meals and beverages (free from grape-
fruit, xanthine- and caffeine-containing products) were
provided at 4:25 AM and 10:25 AM, and a standardized
snack was provide at 2:25 PM, after colchicine admin-
strations.Meals and snacks were identical during each
tudy period. Water was allowed ad libitum starting 2
ours after colchicine administration. Grapefruit juice
as administered as a commercial brand Thirster
00% Grapefruit Juice (Rituals Coffee Co, Columbia,
aryland; lot no.: L 504; expiration date, February 6,
009), and Seville orange juice was provided as hand-
queezed juice from fresh Seville oranges that was
weetened with 1 tablespoon of aspartame (Equal, The
erisant Company, Chicago, Illinois) to ensure pa-
ient compliance. Seville orange juice was obtained by
oaking Seville oranges in tepid water for 20 minutes,
t which time the rind was removed using a peeler.
fter removal of the rind, the oranges were then put
nto a juicer, where the pulp was separated from the
est of the juice. Once juicing was complete, all Seville
range juice was batch frozen to20°C. The necessary
mount of orange juice was removed from the freezer
nd thawed to room temperature 24 hours prior to
dministration. Grapefruit juice was refrigerated at
.8°C to 4.5°C (37°F to 40°F) until dispensed. Neither
uice was analyzed for inhibitory components.
October 2012Subjects were instructed not to take prescription
edications, over-the-counter medications, herbal
roducts, or vitamins or supplements in suprapharma-
ologic doses for 28 days before the first dose of study
edication and throughout the study. They were also
nstructed to abstain from consuming products con-
aining caffeine, xanthine, and alcohol for 48 hours
nd grapefruit or grapefruit-containing products
apart from scheduled study consumption) for 14 days
efore the first study dose and throughout the study.
hey were requested to refrain from engaging in stren-
ous activities at any time during the confinement
eriods.
Subjects were free to withdraw from the study at
ny time for any reason. Furthermore, subjects could
e withdrawn by the investigator in the case of unnec-
ssary risk, AEs, or noncompliance.
Medical history, physical examination, vital signs,
2-lead ECG, routine laboratory testing, serum preg-
ancy screening, and urinary drug screening were per-
ormed during the screening period (days 28 to 2).
edical history, physical examination, vital sign mea-
urements, routine laboratory testing, serum preg-
ancy screening, and urinary drug screening were re-
ssessed at confinement to the clinic on the day before
olchicine dosing (days 1 and 17) and at discharge
rom the clinic at the end of the study (day 22). Urinary
rug screening was repeated on day 1. Seated blood
ressure and heart rate were measured with the patient
n a seated position for5minutes immediately before
olchicine dosing and at 1, 2, and 3 hours postdose on
ays 1 and 18.
Single-dose colchicine 0.6 mg has been studied in
everal pharmacokinetic and drug–drug interaction
tudies23 completed by the sponsor and, furthermore,
otal colchicine exposure following a single 0.6-mg
ose increased by12% to 200% on the basis of Cmax
(maximal observed plasma concentration) and 40% to
240% on the basis of AUC values when given with
several known CYP3A4 and P-gp inhibitors.23 These
studies were completed without significant treatment-
related AEs, with the most likely AEs being general GI
events. In addition, the risk for any serious AEs was
considered low, especially given the study entry crite-
ria. Administration of citrus juices (240 mL twice daily
for 4 days) has been established in other published
drug–food interaction studies to be sufficient for de-
tecting any potential effect on a substrate drug.23 It
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Clinical Therapeuticsshould be noted that a positive control was not used in
either study.
Pharmacokinetic Measurements
Methods of pharmacokinetic measurement were
identical in each study. Blood (6-mL aliquots) was
taken by direct venipuncture before dosing (time 0)
and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 hours
postdose on days 1 and 18 (during confinement) and at
36, 48, 72, and 96 hours postdose (returning to the
clinic on a nonconfined basis). All blood samples (192
mL) were collected into K2-EDTA tubes, kept on ice,
nd then centrifuged at2500g at 4°C for 15 minutes.
lasma samples were stored at 20°C or colder and
ransferred to the bioanalytical laboratory (Cetero Re-
earch), where theywere assayed, by personnel masked
s to the study details or sequence, for colchicine using
validated method of LC-MS/MS.
Pharmacokinetic properties were determined using
inNonlin version 5.0.1 (Pharsight, Mountain View,
alifornia) using standard noncompartmental meth-
ds to determine the following pharmacokinetic
arameters: Cmax, Tmax, AUC0t (calculated by the li-
near trapezoidal method), AUC0 (calculated as
AUC0t  Ct/kel, where kel is the terminal elimination
rate constant), kel (apparent first-order terminal elimi-
ation rate calculated from a semi-log plot of the
lasma concentration versus time curve calculated by
inear least squares regression analysis using the max-
mal number of points in the terminal log-linear phase
eg,3 nonzero plasma concentrations]), t½ (apparent
first-order terminal elimination half-life, calculated as
0.693/kel), CL/F (apparent total body clearance, calcu-
lated as the dose/AUC0), and Varea/F (apparent total
olume of distribution, calculated as the dose/
AUC0  kel]). Samples with significant deviation
from protocol-schedule times were not included in the
analysis.
Statistical Analysis
Statistical analysis was identical in each study. No
formal sample size determination was performed.
However, it was estimated that 24 subjects would be
adequate based on sample sizes used in other published
drug–food interaction studies with citrus juices.23 It
as also been reported to be sufficient for detecting
ignificant interactions with colchicine in drug–drug
nteraction studies undertaken by the sponsor.23
2166Descriptive statistics were used to summarize the
pharmacokinetic data. ANOVA were performed us-
ing the SAS General Linear Model (GLM) procedure
on the log (ln)-transformed geometric mean colchi-
cine AUC0–t, AUC0, and Cmax comparing admin-
istration of colchicine with and without citrus juice.
The ANOVA model included study drug as a fixed
effect and subject as a random effect. Each ANOVA
included calculation of least squares means (LSM),
the difference between study drug LSM and the SE
associated with this difference. Ninety percent CIs
for the ratios were derived by exponentiation of the
CI obtained for the difference between study drug
LSM resulting from the analyses on the ln-trans-
formed geometric mean AUC0–t, AUC0, and Cmax
values. The Wilcoxon signed rank test statistic was
used to analyze Tmax, with a P value 0.05 consid-
ered as significant.
RESULTS
In study 1 (grapefruit juice), all subjects received the
first dose of study medication on September 13,
2008, and the last pharmacokinetic blood sample
was collected on October 4, 2008. In study 2 (Seville
orange juice), all subjects received the first dose of
study medication on February 19, 2009, and the last
pharmacokinetic blood sample was collected on
March 9, 2009.
A total of 22 subjects initiated study 1 (grapefruit
juice) and 24 subjects initiated study 2 (Seville or-
ange juice). Despite the protocol requiring 24 partic-
ipants in each study, the lower number recruited in
study 1 was not considered to have significantly af-
fected the determination of the effect of consecutive
grapefruit juice administrations on single-dose col-
chicine concentrations. Subjects enrolled in either
study and who took 1 dose of study drug were
included in the overall tolerability evaluations for
the relevant study.
One subject was discontinued from each study due
to missing a morning consumption of citrus juice,
which was considered a major protocol violation, in
the second period of the study. Therefore, 21 subjects
in study 1 (grapefruit juice) and 23 subjects in study
2 (Seville orange juice) had paired pharmacokinetic
data analyzed in the statistical ANOVA. There were
no other major protocol deviations. Of the number
of minor protocol deviations that occurred during
the conduct of both studies, none were considered to
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results.
The demographic characteristics of each protocol
population in each study are summarized in Table I. In
study 1 (grapefruit juice), the majority of the subjects
weremale (72.7%) andwhite (90.9%). In study 2 (Sev-
ille orange juice), the majority of the subjects were fe-
male (62.5%), and all were white.
Pharmacokinetic Properties of Colchicine
Administered With and Without Grapefruit Juice
(Study 1)
Plasma concentration versus time curves for col-
chicine appeared remarkably similar after adminis-
tration with and without grapefruit juice (Figure
2A). Nontransformed, arithmetic pharmacokinetic
parameters comparing colchicine administered with
and without grapefruit juice are summarized in Ta-
ble II. There were scant apparent differences in the
pharmacokinetic properties of colchicine adminis-
tered with and without grapefruit juice. Consump-
tion of grapefruit juice slightly decreased the arith-
metic mean colchicine Cmax (1.97 vs 2.17 ng/mL,
respectively), AUC0t (8.82 vs 9.33 ng · h/mL),
Table I. Baseline demographic characteristics of
the subjects in the studies of the effects
of grapefruit and Seville orange juices on
the pharmacokinetic properties of col-
chicine.
Characteristic
Grapefruit Juice
(Study 1) (n  22)
Seville Orange Juice
(Study 2) (n  24)
Age, mean
(range), y 26.9 (21–45) 25.8 (18–40)
Sex, no. (%)
Male 16 (72.7) 9 (37.5)
Female 6 (27.3) 15 (62.5)
Ethnicity, no. (%)
White 20 (90.9) 24 (100)
Black 2 (9.1) 0
Height, mean
(range), in. 70.3 (61.3–75.5) 67.9 (61.9–75.2)
Weight, mean
(range), lb 180.3 (128–235.5) 161.8 (116.5–240.0)
Body mass index,
mean (range),
lb/in2 25.5 (20.6–31.3) 24.5 (19.2–30.6)UC0 (10.85 vs 11.08 ng · h/mL), and kel (0.153
October 2012vs 0.171 h–1) and increased Varea/F (433.1 vs 363.9
L). Median colchicine Tmax was significantly in-
reased with grapefruit juice consumption (1.5 vs
.0 hour; P  0.0156).
The following statistical analyses were under-
taken to determine whether a clinically significant
food–drug interaction was present in accordance
with FDA guidelines.24 The ln-transformed geomet-
ic mean Cmax, AUC0–t, and AUC0 values for col-
chicine administered with and without grapefruit
juice are summarized in Table III. The associated
90% CI of the ratios of the ln-transformed geometric
means for Cmax, AUC0–t, and AUC0 were within
he FDA-accepted interval defining “no interaction”
80%–125%), suggesting that no food–drug inter-
ction is present when colchicine and grapefruit
uice are coadministered.
Time (h)
0.5
0
1.0
1.5
2.0
3.0
2.5
C
on
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/m
L)
C
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nt
ra
ti
on
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0
0.5
1.0
1.5
2.0
3.0
2.5
0 2 4 6 8 10 12 14 16 18 20 22 24
0 2 4 6 8 10 12 14 16 18 20 22 24
Colchicine with grapefruit juice
Colchicine without grapefruit juice
Colchicine with Seville orange juice
Colchicine without Seville orange juice
A
B
Figure 2. Mean plasma colchicine concentrations
after the administration of a single oral
dose of colchicine 0.6mgwith (A) grape-
fruit juice (n 21) and (B) Seville orange
juice (n  23) in healthy subjects.2167
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Clinical TherapeuticsPharmacokinetic Properties of Colchicine
Administered With and Without Seville Orange
Juice (Study 2)
Plasma concentration versus time curves for colchi-
cine after administration with and without Seville or-
ange juice showed marked differences (Figure 2B).
Nontransformed, arithmetic pharmacokinetic proper-
ties comparing colchicine administered with and with-
out Seville orange juice are summarized in Table IV.
Both Cmax and AUC appeared to have decreased dur-
ng coadministration with Seville orange juice. Con-
umption of Seville orange juice decreased arithmetic
ean colchicine Cmax (1.67 vs 2.33 ng/mL, respec-
Table II. Pharmacokinetic properties of colchicine aft
mg with and without grapefruit juice in hea
Property
Colchicine W
Juice
Mean (SD)
AUC0t, ng · h/mL 8.82 (3.00)
AUC0, ng · h/mL 10.85 (4.14)
Cmax, ng/mL 1.97 (0.40)
Tmax, h* 1.5 (1.0–3.0
kel, h
–1 0.153 (0.05)
t1⁄2, h 5.58 (3.51)
Varea/F, L 433.1 (117.2)
CL/F, L/h 62.18 (21.42)
Weight-adjusted CL/F, L/h/kg 0.76 (0.29)
CL/F apparent total body clearance; kel apparent first-o
volume of distribution.
*Median (range).
†An underestimation because the majority of plasma concen
Table III. Geometric mean ln-transformed pharmaco
a single oral dose of colchicine 0.6 mg with
Property
Colchicine With
Grapefruit Juice
(Test)
Colc
Gr
AUC0t, ng · h/mL 8.35
AUC0, ng · h/mL 10.21
Cmax, ng/mL 1.932168ively), AUC0t (7.63 vs 10.26 ng · h/mL), AUC0
(9.15 vs 12.07 ng · h/mL), and t½ (4.91 vs 5.54 hours)
and increased CL/F (70.14 vs 57.03 L/h) and Varea/F
472.2 vs 413.7 L). Median colchicine Tmax was
significantly increased by Seville orange juice con-
sumption (2.0 vs 1.0 hour; P  0.0001). It should be
noted that the t½ and CL/F were poorly estimated
because the terminal elimination slope could not be
estimated.
The ln-transformed geometric mean Cmax, AUC0t,
and AUC0 values for colchicine administered with
nd without Seville orange juice are summarized in
able V. Peak exposure (Cmax) and extent of exposure
administration of a single oral dose of colchicine 0.6
ubjects (n  21).
rapefruit
t)
Colchicine Without Grapefruit
Juice (Reference)
%CV Mean (SD) %CV
34.04 9.33 (3.37) 36.10
38.14 11.08 (3.95) 35.64
20.23 2.17 (0.65) 30.05
– 1.0 (1.0–2.0)
34.78 0.171 (0.05) 29.22
62.79† 4.64 (2.52) 54.29†
27.1 363.9 (97.34) 26.75
34.45 60.25 (21.26) 35.29
37.88 0.74 (0.30) 40.60
erminal elimination rate constant; Varea/F apparent total
ns were not quantifiable by 24 hours postdose.
ic properties of colchicine after the administration of
without grapefruit juice in healthy subjects (n  21).
e Without
uit Juice
ence)
% Ratio
(Test/Reference) 90% CI
.81 94.85 86.47–104.04
.50 97.26 88.08–107.40
.07 93.25 83.07–104.67er the
lthy s
ith G
(Tes
)
rder t
tratiokinet
and
hicin
apefr
(Refer
8
10
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S. Wason et al.(AUC values) for colchicine were decreased by 25%
nd 20%, respectively, during coadministration
with Seville orange juice. The 90% CI ratios of the
ln-transformed geometric means for Cmax, AUC0t,
nd AUC0 were outside of the FDA-accepted in-
erval for “no interaction” (80%–125%), suggesting
hat a clinically significant food–drug interaction
as present when colchicine and Seville orange juice
ere coadministered.
Tolerability
All subjects were monitored for AEs throughout the
confinement portion of the study and queried during
the nonconfinement visits. Blood pressure (sitting for
5 minutes) and pulse were measured prior to dosing
Table IV. Pharmacokinetic properties of colchicine af
mg with and without Seville orange juice in
Property
Colchicin
Orange
Mean (SD)
AUC0t, ng · h/mL 7.63 (2.68)
AUC0, ng · h/mL 9.15 (2.74)
Cmax, ng/mL 1.67 (0.42)
Tmax, h* 2.0 (1.5–3.
kel, h
–1 0.155 (0.04)
t1⁄2, h 4.91 (1.87)
Varea/F, L 472.2 (120.4)
CL/F, L/h 70.14 (17.07)
Weight-adjusted CL/F, L/h/kg 0.99 (0.32)
CL/F apparent total body clearance; kel apparent first-o
volume of distribution.
*Median (range).
Table V. Geometric mean ln-transformed pharmacok
single oral dose of colchicine 0.6 mg with an
Property
Colchicine With Seville
Orange Juice (Test)
Colc
Ora
AUC0t, ng · h/mL 7.25
AUC0, ng · h/mL 8.97
Cmax, ng/mL 1.62October 2012(time 0) and at 1, 2, and 3 hours postdose on days 1
and 18, as well as at screening, each check-in, and
study exit (day 19 or early termination). All subjects
underwent clinical laboratory testing, including hema-
tology, biochemistry, urinalysis, and in women, preg-
nancy testing at screening, baseline, period 2 check-in
(day 17), and prior to discharge from the study (urinal-
ysis was not done at discharge). A full physical exam-
ination was performed at screening, with targeted
physical examinations conducted at baseline, day 18,
and study discharge if needed in response to AEs or
changes in medical history.
Treatment-emergent AEs, defined as those with
onset coinciding with, or subsequent to, the admin-
istration of the drug, are summarized in Table VI.
e administration of a single oral dose of colchicine 0.6
hy subjects (n  23).
h Seville
(Test)
Colchicine Without Seville
Orange Juice (Reference)
%CV Mean (SD) %CV
35.08 10.26 (4.31) 41.98
29.99 12.07 (4.66) 38.59
25.38 2.33 (0.98) 42.09
– 1.0 (0.5–2.0) –
26.55 0.146 (0.05) 37.32
38.09 5.54 (2.39) 43.18
25.49 413.7 (137.1) 33.13
24.34 57.03 (22.01) 38.60
32.03 0.80 (0.30) 37.34
erminal elimination rate constant; Varea/F apparent total
properties of colchicine after the administration of a
hout Seville orange juice in healthy subjects (n 23).
e Without Seville
uice (Reference)
% Ratio
(Test/Reference) 90% CI
9.42 76.99 65.14–90.99
11.34 79.07 69.15–90.40
2.12 76.24 65.83–88.29ter th
healt
e Wit
Juice
0)
rder tinetic
d wit
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nge J2169
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Clinical TherapeuticsThere were no reports of serious AEs, discontinua-
tions because of AEs, or deaths. All AEs were mild or
moderate in intensity. There were no clear between-
treatment differences in either study. In study 1,
treatment-emergent AEs were reported in 2 and 1
patients who received colchicine with and without
grapefruit juice, respectively. In study 2, a higher
percentage of subjects receiving colchicine without
Seville orange juice experienced treatment-emergent
AEs compared with colchicine administered with
Seville orange juice (20.8% vs 4.3%). However, 2 of
the 5 subjects receiving colchicine without Seville
orange juice had multiple AEs related to upper respi-
ratory infection (cough/diarrhea/headache and
pharyngolaryngeal pain/headache, respectively) and
were considered not related to treatment. There was
a report of mild dyspepsia and diarrhea in 1 subject
(4.2%). There were no reports of treatment-related
GI effects. No consistent changes were reported dur-
ing the study with respect to laboratory values, vital
sign measurements, or physical findings. Treatment-
emergent abnormalities were unremarkable, and
none of the values were outside of normal limits,
clinically significant, or directly attributable to the
Table VI. Treatment-emergent adverse events followi
alone and in combination with citrus juice
AE
N
Study 1
Colchicine
0.6 mg Alone
(N  22)
Colc
0.6 mg  G
(N 
Any AE 1 (4.5) 2 (
AE by preferred term*
Headache 1 (4.5)
Cough 0 1 (
Dyspepsia 0
Diarrhea 0 1 (
Chest congestion 0 1 (
Pharyngolaryngeal pain 0 1 (
Pyrexia 0
Pain 0
MedDRA Medical Dictionary for Regulatory Affairs.
*According to MedDRA Version 10.1.study medication. o
2170DISCUSSION
Consumption of grapefruit juice (240 mL twice daily
for 4 consecutive days) had no statistically or clini-
cally significant effects on the pharmacokinetic
properties of colchicine following the oral adminis-
tration of a single 0.6-mg dose in healthy subjects in
a fasted state except for a marginal but statistically
significant increase in median Tmax, from 1.0 to 1.5
hours (P  0.0156). Paradoxically, consumption of
Seville orange juice (240 mL twice daily for 4 con-
secutive days) decreased colchicine Cmax and overall
otal colchicine exposure (AUC values) by 25%
nd 20%, respectively, on the basis of ln-trans-
ormed geometric mean values. Median colchicine
max was also significantly increased, from 1.0 to 2.0
hours (P  0.0001), delayed by 1 hour during Sev-
lle orange juice consumption. The clinical signifi-
ance of this finding is unknown. The findings of
hese 2 studies were unexpected, because previous
tudies and case reports in the literature indicated
hat both citrus juices would be expected to increase
ystemic colchicine exposures.
Mechanistically, it has been well established in the
ublished literature that grapefruit juice is an inhibitor
al administration of a single dose of colchicine 0.6 mg
efruit or Seville orange) to healthy subjects.
Subjects Experiencing AEs (%)
Study 2
uit Juice
Colchicine
0.6 mg Alone
(N  24)
Colchicine
0.6 mg  Seville Orange Juice
(N  23)
5 (20.8) 1 (4.3)
2 (8.3) 1 (4.3)
2 (8.3) 0
1 (4.2) 0
1 (4.2) 0
0 0
1 (4.3) 1 (4.3)
1 (4.2) 0
1 (4.2) 0ng or
(grap
o. of
hicine
rapefr
21)
9.5)
0
4.8)
0
4.8)
4.8)
4.8)
0
0f the intestinal CYP3A4 and can lead to clinically
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S. Wason et al.significant interaction with certain drugs that are
CYP3A4 substrates (eg, felodipine, amiodarone, ator-
vastatin), resulting in increased systemic exposure (for
recent reviews, see Seden et al,4Won et al,5 andHanley
t al6). This is believed to be the primary mechanism by
hich grapefruit juice can increase systemic drug ex-
osure. Bergamottin and 6=,7=-dihydroxybergamottin
re believed to be the main compounds effecting
YP3A4 inhibition induced by grapefruit juice and
imilarly by Seville orange juice.7 However, it has
lso been suggested that inhibition of intestinal P-gp
ay also be involved in grapefruit juice–drug inter-
ctions, resulting in increased systemic exposure. In-
eed, grapefruit juice has been reported to inhibit
-gp–mediated efflux transport of colchicine in
itro.25 More recently, these investigators have re-
ported that GI absorption of colchicine is decreased
throughout the small intestine by the combined ef-
fects of P-gp and multidrug resistance–associated
protein 2 transepithelial efflux dominating the GI
permeability process.26 The clinical relevance of this
is not known because these findings have not been
reproduced in human subjects or in patients with
known P-gp substrates.4
The paradoxical decrease in colchicine exposure
during coadministration with Seville orange juice was
unexpected and raises a number of questions. Other
mechanisms have been implicated in interactions of
citrus juice (grapefruit juice or sweet orange juice) with
medications, including inhibition of uptake transport-
ers such as organic anion-transporting polypeptides
(OATPs) (for reviews, see Bailey,27 Seden et al,4 Won
et al,5 and Hanley et al6). Grapefruit juice and sweet
range juice have been reported to inhibit OATP-me-
iated drug transport in vitro.28,29 Naringin has been re-
ported to be one of the components of grapefruit juice
involved in OATP inhibition.30 Inhibition of OATP-me-
diated enterocyte drug uptake (ie, active GI absorption)
by grapefruit juice and/or sweet orange juice has been
reported to significantly decrease peak exposures and ex-
tent of systemic exposures of certain drugs that undergo
active OATP-mediated GI absorption (eg, fexofena-
dine,28 celiprolol,31 talinolol,32 atenolol,33 aliskiren,34
ciprofloxacin,35 and etoposide36).
It is unknown whether colchicine undergoes OATP-
ediated GI absorption. Furthermore, grapefruit juice
ad no effect on the pharmacokinetic properties of col-
hicine in the present study. It might be hypothesized
hat some other, unknown component of Seville or- p
October 2012nge juice not present in grapefruit juice might be re-
ponsible for inhibition of colchicine absorption via
he OATP-mediated pathway. There are few studies on
he interaction of Seville orange juice with agents apart
rom felodipine,7 where it behaves similarly to grape-
ruit juice. In addition, there have been few studies on
he composition of Seville orange juice, although the
urocoumarin bergapten has been identified as a com-
onent of Seville orange juice, which is not a constitu-
nt in grapefruit juice.7 These investigators suggested
that Seville orange juice appears to selectively inhibit
intestinal CYP3A4 (and not P-gp), whereas grapefruit
juice inhibits both intestinal CYP3A4 and P-gp.7 Both
max and AUCwere significantly decreased during coad-
ministration of Seville orange juice in the present study
(ln-transformed geometric mean Cmax and AUC values
were reduced by25% and20%, respectively). Other
Kparameters affected during concurrent administration
f colchicine and Seville orange juice include Tmax, which
was increased by 1 hour (median).
Despite no findings of clinically significant interaction
between grapefruit juice consumption and the single-dose
pharmacokinetic properties of colchicine in this study,
the FDA has maintained that grapefruit juice is a moder-
ate CYP3A4 inhibitor in the drug labeling for approved
colchicine, which necessitates adjusted, lower doses of
colchicine because of a potential for increased systemic
colchicine exposure and AEs. Specific recommendations
for dosing adjustmentswhen using colchicine togetherwith
moderate CYP3A4 inhibitors (eg, grapefruit juice) in the
prophylaxis or treatment of patients with gout flares are
available in the full prescribing information. Alternatively,
normal doses of colchicine can be used, but grapefruit-con-
taining products should be avoided.37
Review of the literature reveals few data regarding the
potential for interaction between colchicine and grape-
fruit juice. A single case report of near-fatal acute colchi-
cine toxicity with concurrent consumption of grapefruit
juice was reported in an 8-year-old girl with familial
Mediterranean fever.38 This patient had been prescribed
olchicine 2 mg/d for 10 months and, during the 2
onths preceding hospital admission, was ingesting
000mL/d of grapefruit juice. She developed fever, recur-
ent vomiting, severe abdominal pain, and a sore throat.
he was hospitalized 2 days later for an acute attack of
amilialMediterranean fever. By day 2, the patient devel-
ped circulatory shock and pancytopenia, requiring intu-
ation, fluid support, inotropic agents, fresh frozen
lasma, vitamin K, and granulocyte colony-stimulating
2171
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Clinical Therapeuticsfactor. The patient’s clinical condition improved and sta-
bilized during the following days. Delayed pathologies
present in the second week of hospitalization included
practically total alopecia, atonic falls, weakness, and an
elevated white blood cell count, with no signs of infec-
tion. These symptoms resolved by the patient’s discharge
from the hospital on day 24. Based on a thorough search
of the published literature, there have been no other re-
ports concerning the potential interaction between grape-
fruit juice and colchicine to the authors’ knowledge.
CONCLUSIONS
In consideration of the fact that a positive controlwas not
used in either study, based on mechanism of action as a
moderate CYP3A4 inhibitor, grapefruit juice unexpect-
edly did not affect the pharmacokinetic properties of col-
chicine. Paradoxically, Seville orange juice reduced Cmax
andAUC and increased Tmax. Colchicine administered in
ombination with either juice was well tolerated.
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